DOW JONES25,766.64-1190.95 -4.42%
S&P 5002,978.76-137.63 -4.42%
NASDAQ8,566.48-414.30 -4.61%

JMP Securities Maintains Market Outperform on Aimmune Therapeutics, Raises Price Target to $44

JMP Securities analyst Liisa Bayko maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Market Outperform and raises the price target from $40 to $44.

Benzinga · 02/03/2020 14:07

JMP Securities analyst Liisa Bayko maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Market Outperform and raises the price target from $40 to $44.